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INTRODUCTION 
The need for an expert consensus statement of the Polish Cardiac Society and the Polish Society 
of Cardiothoracic Surgeons on transcatheter mitral valve repair and replacement in patients with 
significant mitral valve regurgitation (MR) has been triggered by dynamic progress in the 
development of new technologies, publication of data from randomized clinical trials and 
registries, increasing availability of these techniques and growing experience of Polish 
operators. While in case of patients with primary MR and acceptable operative risk, cardiac 
surgery is the treatment of choice (the primary surgical repair is associated with a better 
prognosis than valve replacement), the indications and long-term results of surgical treatment 
in patients with secondary (functional) MR related to left ventricular dysfunction are less 
documented, except in patients undergoing simultaneous revascularization or replacement of 
the aortic valve [1]. Group of patients with heart failure (HF) and secondary MR have increased 
risk of mortality, higher incidence of hospitalizations for decompensated HF, and deterioration 
in the quality of life. The necessity to develop alternative treatment methods for patients with 
increased or prohibitive surgical risks with both primary and secondary MR led to rapid 
advances in transcatheter mitral valve repair (TMVR). The current document primarily 
discusses edge-to-edge TMVR techniques, which have been validated in randomized clinical 
trials and large registries in populations of patients with chronic primary and secondary MR. 
Other techniques of TMVR and transcatheter mitral valve implantation (TMVI) are at the early 
stages of clinical testing and are currently not available in Poland, except in ongoing clinical 
trials. 
 
TRANSCATHETER METHODS OF MITRAL VALVE REPAIR 
Transcatheter mitral valve interventions can be divided into: 
Repair methods using CE-marked devices 
1. Percutaneous repair by edge-to-edge approximation of anterior and posterior mitral valve 
leaflets (MitraClip and PASCAL devices), which mimics the surgical method developed by 
Alfieri. 
2. Percutaneous reduction of mitral annulus dilatation (annuloplasty): 
— indirect (the device is implanted in the coronary sinus [Carillon]); 
— direct annuloplasty (Cardioband device). 
3. Transapical implantation of artificial tendinous chords (Neochord, Harpoon). 
4. Combination of the techniques listed in subparagraphs 1–2. 
Techniques of transcatheter mitral valve implantation (TMVI) 
1. Implantation of balloon-expandable transcatheter aortic valve implantation (TAVI) 
bioprosthesis into a malfunctioning surgically implanted biological prosthesis (valve-in-
valve) (CE mark for Sapien valve), surgically implanted mitral ring (valve-in-ring), or 
mitral annular calcification (valve-in-MAC). 
2. Implantation of dedicated TMVI device either via transseptal (still under clinical 
investigation ) or transapical access (currently one bioprosthesis with CE mark). 
Two TMVR (percutaneous edge-to-edge repair) systems are available in Poland: MitraClip 
(Abbott Vascular, Santa Clara, CA, USA) and recently introduced Pascal (Edwards 
Lifesciences, Irvine, CA, USA). It should be emphasized that most of the data from 
randomized clinical trials, providing evidence-based medicine consistent results, and 
clinical experience (over 100 000 patients) relate primarily to the MitraClip edge-to-edge 
repair system.  
 
THE EDGE-TO-EDGE REPAIR: MITRA CLIP SYSTEM 
Clinical trial results 
Primary (degenerative) mitral regurgitation 
Most of the currently available recommendations of scientific societies are based on the 
EVEREST study (Endovascular Valve Edge-to-Edge REpair STudy) and EVEREST II 
utilizing the MitraClip system. In the EVEREST study, in patients disqualified from 
conventional surgery, the use of this system was safe and technically feasible. MR grade 
reduction was less effective than surgical repair/replacement due to the higher prevalence of 
residual MR. Nevertheless, it reduced the severity of MR (to ≤2 + in approximately 75% of 
patients), clinical symptoms, and left ventricular remodeling [2]. The EVEREST II study 
involving 279 patients was the only randomized trial comparing the transcatheter approach to 
conventional surgery in patients with mostly primary MR. In the intention-to-treat analysis, the 
transcatheter procedure was less effective in MR reduction and in terms of the composite 
endpoint (death, surgery for mitral valve dysfunction, and grade 3+/4+ MR at 2 years). This 
was mainly due to the fact that 20% of patients treated with MitraClip required reintervention 
within one year of the procedure. However, there were no differences in the mortality rates. 
Percutaneous treatment emerged as superior in terms of safety at 30 days, which was driven by 
decreased transfusions rate. At the same time, 37 patients (20%) in the percutaneous-repair 
group subsequently required mitral-valve surgery in the early post-operative period [3, 4]. It is 
important to remember that in EVEREST II, 73% of patients had primary MR and relatively 
low operational risk. At the same time, modern European registries include patients with 
secondary MR and high or prohibitive operative risk. There is currently an ongoing randomized 
controlled trial to compare the clinical outcomes of MitraClip system versus surgical repair in 
patients with primary mitral insufficiency who are at moderate surgical risk (REPAIR MR, 
NCT04198870). 
 
Secondary (functional) mitral regurgitation  
Randomized trials 
The data concerning procedural success rate and effectiveness of MitraClip comes from two 
randomized clinical trials: MITRA-FR (Percutaneous Repair with the MitraClip Device for 
Severe Functional/Secondary Mitral Regurgitation) and COAPT (Cardiovascular Outcomes 
Assessment of the Mitra-Clip Percutaneous Therapy for Heart Failure Patients with Functional 
Mitral Regurgitation), published in 2018. The MITRA-FR study enrolled 304 patients with HF, 
severe secondary MR, and impaired left ventricular ejection fraction (LVEF) (15%–40%) 
despite guideline-recommended optimal medical therapy and cardiac resynchronization therapy 
(CRT). Patients were randomized (1:1) to receive either TMVR or conservative treatment. The 
number of periprocedural complications was low. At discharge, 91.9% of patients had a 
reduction in MR to ≤2+. Regardless, there were no significant differences in the primary 
endpoint rate (death or unplanned hospitalization for HF) at 12 months (54.6% vs 51.3%). The 
mortality rate (24.3% vs 22.4%) or unscheduled hospitalization rate (48.7% vs 47.4%) did not 
differ significantly between groups. Both groups achieved comparable symptomatic 
improvement (NYHA [New York Heart Association] class reduction at one year). Complete 
clinical data was provided on as many as 99% of patients. The limitation of the study was an 
incomplete echocardiographic follow-up [5]. 
The COAPT study enrolled 614 patients with moderate to severe secondary MR and HF 
(NYHA II–IV) despite the use of maximal doses of guideline-recommended medical therapy 
and implantation of CRT (36.5%). The cause of cardiomyopathy was ischemic in 60.7% of the 
patients and nonischemic in 39.3%. Patients were randomly assigned to MitraClip — device 
group (n = 302) or medical therapy alone — control group (n = 312). The study revealed 
significantly lower rate of hospitalization for heart failure (35.8% vs 67.9%; HR 0.53; 95% CI, 
0.40–0.70; P <0.001; NNT= 3.1) and lower all-cause mortality (29.1% vs 46.1%; HR 0.62; 
95% CI, 0.46–0.82; P <0.001) within 24 months of follow-up in patients with device-based 
treatment than with medical therapy alone. Moreover, their quality of life was significantly 
better, functional capacity was more preserved, and mitral regurgitation and left ventricular 
end-diastolic volume were reduced (secondary endpoints) [6].  
The discrepancies between the results of both abovementioned trials may be due to 
heterogeneous inclusion criteria and direct effects of the procedure (Table 1), which requires a 
comment. The studied groups differed in sample size (304 vs 614 patients) and the duration of 
clinical follow-up for the primary endpoint (12 vs 24 months).  
In COAPT, the primary endpoint was hospitalization for HF, while in MITRA-FR, it was a 
composite endpoint (all-cause mortality and unscheduled hospitalization for HF). Inclusion 
criteria and MR definition were also different (MITRA-FR: effective regurgitant orifice area  
[EROA] ≥20 mm2 and/or regurgitant volume >30 ml; COAPT: EROA ≥30 mm2 and regurgitant 
volume >45 ml), as well as LVEF (MITRA-FR: 15%–40%; COAPT: 20%–50%) and end-
systolic left ventricle diameter (COAPT: <70 mm, lack of this criterion in MITRA-FR). As a 
result, in the MITRA-FR study, the mean left ventricular volume was higher (135 ml/m2 vs 101 
ml/m2), and the mitral regurgitation was less severe (EROA 31 ± 10 vs 41 ± 15 mm2), with 
comparable LVEF values (33 ± 7 vs 31 ± 7%). Therefore, in the COAPT trial, the percentage 
of patients with severe MR (EROA ≥40 mm3) was significantly higher (41 vs 16%). Although 
the percentage of successful procedures in the MITRA-FR study was high, it was significantly 
higher in the COAPT study. Inclusion in the COAPT study required optimization of 
pharmacological therapy, confirmed by an independent team of experts prior to enrolment. 
MITRA-FR imposed less strict inclusion criteria, which is more similar to “real-world” practice 
[7]. Detailed post-hoc analyzes indicated that the inclusion and exclusion criteria for both trials 
led to the COAPT study enrolling patients with clinically predominant MR as the major 
mechanism of heart failure. In contrast, the MITRA-FR study included more patients with 
severe left ventricular dysfunction and a relatively less severe MR as a major cause of HF. 
Results of the extended 3-year follow-up of patients in the COAPT study confirmed the 
effectiveness of TMVR with the MitraClip system in reducing mortality and rehospitalization 
rates and improving the quality of life (Mack et al. TCT 2019).  
From a practical point of view, patients enrolled by the multidisciplinary Heart Team for 
MitraClip TMVR should meet the criteria of the high probability of a favorable response to this 
type of treatment.  
The ongoing Reshape-HF2 trial (A Clinical Evaluation of the Safety and Effectiveness of the 
MitraClip System in the Treatment of Clinically Significant Functional Mitral Regurgitation 
[Reshape-HF2], https://clinicaltrials.gov/ct2/show/NCT02444338) has similar eligibility 
criteria in terms of MR as COAPT study and intermediate criteria between COAPT and 
MITRA-FR for the assessment of left ventricular dysfunction. 
To date, we did not obtain the results of randomized clinical trials comparing the effectiveness 
of transcatheter and surgical repair of mitral valve insufficiency in patients with secondary 
(functional) MR. The evaluation of these two strategies is the subject of an ongoing 
MATTERHORN study (Multicenter, Randomized, Controlled Study to Assess Mitral vAlve 
reconsTrucTion for advancEd Insufficiency of Functional or iscHemic ORigiN).  
 
Registries 
Important data on “edge-to-edge” TMVR comes from registers — pan-European ACCESS-EU 
and German TRAMI. In the ACCESS-EU registry, approximately 70% of patients had 
secondary MR. MitraClip procedures were highly effective (99.6%) and safe (30-day mortality 
3.4%). Additionally, after six months, 80% of patients achieved MR reduction to ≤2+ and 
symptomatic improvement to NYHA class I/II. The 6-month mortality rate was 11.2%. Data 
from the TRAMI registry of 486 patients indicate low (2.5%) in-hospital mortality and 12.5% 
mortality after three months period [8, 9]. Expanding the anatomical indications for the 
procedure beyond those applicable in the EVEREST trial does not reduce the effectiveness of 
this method. 
The Getting Reduction of Mitral Insufficiency by Percutaneous Clip Implantation (GRASP) 
registry compared patients who met the EVEREST criteria with those whose mitral valve 
anatomy was less favorable. It has been demonstrated that in both groups, incidence rates of the 
composite endpoint were similar, which indicates that it is justified to extend the inclusion 
criteria to inoperable/high-risk patients for whom the procedure is technically feasible. 
Similarly, the MitraSwiss, TRAMI, and Taramasso et al. Registries covering patients with 
primary and secondary MR showed that the long-term prognosis in groups not strictly meeting 
EVEREST criteria was not inferior to patients who did [9–11]. 
Increasing experience with the MitraClip system, especially in centers with a trained team and 
sufficient experience (≥50 procedures), shows that edge-to-edge repair may be a safe alternative 
to surgery in selected cases. However, the MR recurrence rate is significantly higher than in the 
case of surgical treatment. 
A meta-analysis that included 1015 patients from 7 studies comparing both techniques has 
shown comparable 30-day and 6-month mortality rates despite higher EuroSCORE in the 
transcatheter group. Nevertheless, the severe MR recurrence rate was almost five times higher 
in the TMVR group [12]. It should be emphasized that recurrent MR, as well as residual 
regurgitant jet size are strong predictors of long-term mortality in patients after mitral valve 
repair procedures in both primary and secondary mitral regurgitation [1]. 
Clinical experience with the PASCAL system (another edge-to-edge TMVR system) includes 
registry studies from European heart valve centers. They indicate the effectiveness of this 
system in reducing MR and functional improvement of HF, mainly in patients with secondary 
MR [13]. The PASCAL system has recently been registered in Poland.  
 
Recommendations of scientific societies 
Current European Society of Cardiology/European Association for Cardio-Thoracic Surgery 
(ESC/EACTS) Guidelines for the management of valvular heart disease had been published in 
2017, so they reflect an early stage of development of emerging, innovative techniques of 
TMVR when the results of randomized trials for patients with secondary MR were not 
available. The guidelines included only the EVEREST and EVEREST II findings, which served 
as the basis for the approval of the MitraClip system in the US in patients with primary MR. 
Recently, the Food and Drug Administration (FDA) has extended the approval to patients with 
secondary MR in accordance with the results of the COAPT study. The new ESC and EACTS 
guidelines will be published in 2021. Current ESC guidelines highlight the importance of Heart 
Team decision-making and the necessity for comprehensive and individualized evaluation of 
each patient potentially eligible for TMVR. While surgery is the preferred treatment, 
transcatheter procedures are a viable therapeutic alternative for patients with chronic 
symptomatic HF (NYHA II–IV), severe MR and inoperable or high-risk patients with a life 
expectancy of at least one year.  
The echocardiographic parameters are additional criteria that the patient must meet for the 
procedure to be considered feasible (recommendation class IIb, level of evidence C). The 2017 
ESC Guidelines take into consideration patients with secondary MR. Also, in this group, repair 
procedures may be considered in patients with severe and symptomatic, despite optimal 
treatment, secondary MR, in patients, whom the Heart Team did not find suitable for surgery 
or with a very high perioperative risk (class IIb recommendation, level of evidence C). 
The  American College of Cardiology/American Heart Association guidelines for the 
management of patients with valvular heart disease published in 2021 include new, less 
restrictive recommendations for edge-to-edge TMVR, which extend the pre-existing 
indications, in the case of: a) severe primary MR in symptomatic patients (NYHA class III–IV) 
with high or prohibitive surgical risk, favorable valve anatomy and estimated survival time over 
one year (class of recommendation IIa); b) severe secondary MR associated with left ventricular 
dysfunction (LVEF <50%), symptoms in functional classification II–IV despite optimal 
pharmacotherapy of HF, favorable valve anatomy on echocardiography, LVEF 20%–50%, left 
ventricular end systolic diameter ≤70 mm and pulmonary artery systolic pressure ≤70 mm Hg 
(class of recommendation IIa) [14]. If coronary revascularization is not necessary, the 
recommendations for surgical treatment in this particular group of patients are class IIb. The 
classification algorithm for transcatheter mitral valve procedures based on the American Heart 
Association/American College of Cardiology guidelines is presented in Figure 1.  
 
Determining patients' eligibility for TMVR 
The role of the multidisciplinary Heart Team in determining proper treatment strategies 
Decision-making for intervention should be made by a “Heart Team” with particular expertise 
in valvular heart disease, comprising cardiologists, cardiac surgeons, interventional 
cardiologists, anesthetists, and imaging specialists, experienced in mitral valve anatomy 
assessment and interventional imaging in structural heart disease. In some cases, the 
professional opinion of a radiologist performing multislice computed tomography of the heart 
is necessary.  
Due to the high risk associated with comorbidities, patients should be treated in centers with 
highly specialized multidisciplinary teams, trained in both surgical and transcatheter procedures 
to deliver high-quality care (“heart valve centers”). In addition to an interventional cardiologist 
or cardiac surgeon experienced in a given interventional technique, a cardiologist specializing 
in interventional imaging plays an important role in a minimally invasive valve repair or 
implantation procedure, because unlike other transcatheter procedures (e.g., TAVI), the use of 
fluoroscopy is of less importance and proper planning of the procedure and surgical navigation 
is possible only based on a transesophageal examination, optimally with three-dimensional 
imaging. Patients treated with TMVR should undergo a periodic clinical and echocardiographic 
evaluation to exclude late complications and determine long-term efficacy. Heart Team opinion 
is of particular importance in patients with primary MR, in whom conventional surgical 
treatment is the procedure of choice, and the referral for transcatheter treatment applies to the 
surgically ineligible patients. In the group of patients with secondary MR, it is crucial to provide 
optimal pharmacological therapy in accordance with the guidelines and, if applicable, 
implantation of CRT. Patients eligible for the transcatheter procedure are those with 
symptomatic HF despite pharmacotherapy optimization. Cooperation with HF specialists may 
be helpful to facilitate patient management and deciding on heart transplant or left ventricular 





Clinical evaluation  
1) Symptomatic HF (NYHA II–IV) despite optimal medical pharmacotherapy in 
maximum tolerated doses, in line with the guidelines for the management of heart 
failure, including CRT implantation if indicated, as well as complete revascularization.  
2) Shared decision of multidisciplinary heart team on TMVR. In patients with primary 
MR, edge to edge TMVR can be considered in inoperable or high-risk surgical patients. 
However, in case of secondary MR, the edge-to-edge repair is the treatment of choice 
in patients meeting clinical and anatomical criteria who are not candidates for surgical 
revascularization. Transcatheter edge-to-edge repair may also be beneficial in patients 
waiting for a heart transplant or LVAD implantation. 
3) Estimated life expectancy should be at least 12 months in patients with primary MR. In 
patients with secondary MR, the futility of interventions in patients unlikely to benefit 
from the treatment must be taken into account.  
4) It is recommended to avoid surgeries in patients with low chance of expected quality of 
life improvement due to their general condition (emaciation, advanced frailty syndrome) 
and comorbidities. Important determining factors include the presence of severe 
pulmonary hypertension, severe right ventricular dysfunction with significant tricuspid 
regurgitation, extremely high NT-proBNP levels (>5000 pg/ml) and LVEF <20%. The 
coexistence of pulmonary hypertension, right ventricular dysfunction and LVEF <20% 
drastically worsens the prognosis.  
5) Optimal pharmacotherapy. 
Since the COAPT study confirmed the benefit of edge-to-edge repair treatment in patients for 
whom optimization of pharmacotherapy was an essential element of referral for the procedure, 
it is recommended that all implanting centers should assess the pharmacotherapy in the 
screening protocol following ESC recommendations.  
It is recommended to consider the following drug groups: 1) angiotensin-converting-enzyme 
inhibitors/angiotensin II receptor antagonist or sacubitril/valsartan; 2) a beta-blocker in an 
optimal dose – with dose adjustments based on the patient's heart rate and blood pressure; 3) 
mineralocorticoid receptor antagonists; 4) loop diuretic; 5) ivabradine. The pharmacotherapy 
mentioned above should be continued for a minimum of 3 months in an outpatient clinic before 
deciding on the referral. The ineffectiveness of the therapy or lack of the possibility of its further 
optimization should be documented.  
 
 
Echocardiographic criteria  
Patients’ referral for procedures performed without extracorporeal circulation is performed 
based on information obtained by three-dimensional (3D) transthoracic and transesophageal 
echocardiography. Echocardiographic evaluation should provide the following information on 
1) the severity and mechanism of MR; 2) the validity of the procedure based on the MR 
assessment in relation to the volume of the left ventricle by dividing patients into groups with 
“proportionate” and “disproportionate” MR in patients with secondary regurgitation; 3) 
anatomical assessment of the mitral valve and subvalvular apparatus in terms of feasibility of 
the procedure; 4) evaluation of other parameters influencing the long-term outcomes of the 
procedure (left and right ventricular function, presence of other valvular diseases, including 
tricuspid valve regurgitation, presence of pulmonary hypertension); 5) detection of 
contraindications. 
Primary MR 
1) Presence of severe MR based on qualitative, semi-quantitative, and quantitative 
assessments. 
2) No anatomical contraindications. 
Secondary MR 
1) Presence of severe MR based on qualitative, semi-quantitative and quantitative 
parameters assessment — at least moderate to severe MR as assessed with qualitative 
parameters (EROA ≥0.3 cm2, EF ≥40%). Due to the asymmetric nature of the 
regurgitant orifice, quantitive assessment should be based, if possible, on a 3D 
reconstruction, and where 3D techniques are not available, an integrated approach is 
strongly recommended instead of referring to single measurements. Taking into account 
vena contracta measured in two perpendicular planes, including along the coaptation 
line. 
2) Disproportionate MR should be evaluated as EROA to left ventricular end-diastolic 
volume (LVEDV) ratio (the higher the EROA/LVEDV [mm2/ml × 100] ratio, the 
greater the profitability of the procedure compared to pharmacotherapy) or regurgitant 
volume to EDV ratio (RV/LVEDV). Left ventricular volume alone and LVEF 
(especially <20%) are also important prognostic factors for lack of clinical 
improvement. Additionally, the presence of global vs. regional wall motion 
abnormalities, presence of symmetrical vs. asymmetrical regurgitant jet is assessed. 
This concept facilitates the decision-making process, but it is not the only parameter 
that should be taken into consideration. Simply put — it is reasonable to rule patients as 
eligible for the procedure, with LVEF ≥20% and left ventricular end systolic diameter 
≤70 mm; however, these parameters, especially regarding the end-diastolic dimension 
of the left ventricle, should be treated as indicative only and should be interpreted 
depending on the clinical condition, the severity of regurgitation, nature of left 
ventricular remodeling and the morphology of the valve itself.  
3) Shared echocardiographic criteria for primary and secondary MR  
1. Primary morphological criteria for patient eligibility were based on a pre-specified 
EVEREST study protocol. Key inclusion criteria included a regurgitant jet origin 
associated with the abnormal coaptation of A2 to P2 segments and the mitral valve 
area was equal to or greater than 4.0 cm2. Currently, it is more common to use the 
criteria determining the feasibility of the intervention based on extensive experience 
and new surgical techniques, mainly from German and American centers. The 
evolution of the MitraClip system is also significant (introducing two lengths and 
widths of the clip arms and the possibility of independently gripping the leaflets in 
the G4 system). Nevertheless, mitral stenosis following Mitra-Clip insertion remains 
the primary concern, particularly in patients who require more than one clip due to 
broad regurgitant jet. Published in 2013, an expert opinion of the international group 
of experienced operators and echocardiography specialists divide patients into three 
groups in terms of mitral valve (MV) morphology:  
a) Ideal valve morphology for a MitraClip procedure: MR originating from the mid-
portion of the valve (A2P2), no evidence of calcification in the grasping area of the 
A2 and/or P2 scallops, mitral valve area >4.0 cm2 (3D-echo planimetry 
measurements are the first choice method), posterior leaflet mobile length ≥10 mm, 
coaptation depth <11 mm, a width of the flail segment ≥15 mm, or flail gap ≥10 
mm.  
b) Unsuitable valve morphology for a MitraClip procedure: Severe calcification in the 
grasping area, perforated mitral leaflets or clefts, increased risk of post-operative 
mitral stenosis (mitral valve area <3.5–4.0 cm2 — EVEREST exclusion criterion, 
which is not currently a key decision parameter), length of posterior leaflet <7 mm, 
Barlow’s disease with multiple mitral regurgitation jets, presence of a broad jet 
especially in patients with intermediate mitral valve area at baseline, which may 
indicate the need for multiple clips in order to successfully approximate leaflets and 
increase coaptation, rheumatic valve disease — with restriction in systole und 
diastole or endocarditic valve disease. The use of longer clips and the ability to 
independently grasp the leaflets make the limitations resulting from a large 
coaptation gap less significant. 
c) Complex: intermediate morphology between a and b. The feasibility of the 
procedure depends on the experience of the center and the operators. 
2. The exclusion criteria for the MitraClip therapy are the evidence of intracardiac, 
inferior vena cava or femoral venous thrombus, cardiac tumor, or active endocarditis. 
Understanding interatrial septum anatomy is of great importance. The presence of 
interatrial masses such as aneurysm, lipomatous hypertrophy of the interatrial septum, 
patent foramen ovale makes the procedure more challenging. 
The feasibility of the procedure in other cases depends mainly on the experience of the operators 
and the quality of periprocedural imaging [15]. The procedure can be performed safely in 
patients who previously underwent transcatheter left atrial appendage occlusion. 
 
Recommendations  
Determining patients’ eligibility for edge-to-edge TMVR should be in alignment with the 
consensus recommendations developed in centers with expertise in both surgical and 
percutaneous treatment of mitral valve disease by an experienced multidisciplinary team. It is 
the first choice treatment in patients with severe degenerative MR and in groups with high or 
prohibitive surgical risk. In patients with secondary MR and HF, TMVR may be considered as 
long as a medical therapy has already been dose-optimized and CRT-D had been implanted, if 
indicated.   
As the COAPT clinical trial consistently demonstrated the benefits of MitraClip in patients with 
secondary MR, it is advisable to select patients whose clinical and anatomical characteristics 
are similar to the COAPT eligibility criteria and the likelihood of symptomatic improvement is 
high. 
 
Planning the procedure and post-operative care 
Procedural aspects 
The procedure is performed under fluoroscopy and with continuous transesophageal 
echocardiography (TEE) guidance with 3D imaging. It is imperative to establish means of 
communication in relation to the anatomy of the heart that is understood by the entire team 
(nomenclature of mitral valve [MV] segments, directions of movement [medial-lateral, 
anterior-posterior]).  
TEE is crucial, from selecting the transeptal puncture site (fossa ovalis, approximately 4 cm 
above the mitral annulus and at a safe distance from the aorta and free atrial wall) until the last 
clip is released. The site of transseptal puncture depends on the origin of mitral regurgitation 
jet (for medially directed jet, it is more beneficial to puncture the septum lower, in the bicaval 
projection, than for jet directed laterally). After septal puncture, it is necessary to confirm the 
safe location of the guidewire in one of the pulmonary veins and during the navigation of the 
MitraClip device to confirm that it does not touch the atrium walls. If it is not feasible to insert 
a guidewire into the pulmonary vein (e.g., a significantly enlarged atrium) preshaped stiff 
guidewire (e.g., Safari or similar) may be used and left behind in the atrium cavity until the 
guiding catheter is inserted. Optimal 2D imaging is usually feasible by tilting the TEE probe 
backward and placing it in the axis of the mitral valve and the left ventricle. The same axis 
should also be the trajectory of the clip insertion into the left ventricle, which is achieved by 
the proper introduction of the delivery system into the septum, its rotation, and setting the 
catheter deflection control knobs. Deviations from these rules usually cause difficulties in 
imaging of the clip, skewed trajectory when passing the valve (diving), and subsequently 
uneven grasp of the leaflets leading to increased risk of valve deformation after the release of 
the device. The technique which facilitates and shortens this stage of the procedure is the 
intraoperative real-time 3D TEE imaging (RTTEE3D). The surgical view of the MV in 
RTTEE3D allows the maneuvers to position the clip arms perpendicular to the line of coaptation 
at the intended implantation site. The crossing of the valve is usually done under the guidance 
of 2D TEE, preferably in 2 perpendicular planes (X-plane). After entering the ventricle, the 
position of the clip is once more assessed with RTTEE3D. The evaluation allows as well to 
determine if the clip orientation is perpendicular to the line of MV coaptation.  
The introduction of a new generation of MitraClip devices, including wider clips, allows 
obtaining a reduction of MR after a single clip application in a significant percentage of cases. 
However, in the presence of a broad jet, which requires multiple clips, it is reasonable to use 
the first one medially and the next ones laterally, which allows avoiding subsequent 
implantation in close proximity to the commissure. 
To grasp the leaflets of the mitral valve, a 3-chamber mid-oesophageal view is sufficient, in 
which a cross-section through the arms of the device is visible simultaneously with the anterior 
and posterior leaflet (left ventricular outflow tract [LVOT] view). However, it is optimal to use 
two perpendicular views (three-chamber and two-chamber mid-oesophageal view — LVOT 
and intercommissural view), which allows for proper navigation, as well as to determine when 
the clip is adequately positioned and whether arm orientation is perpendicular to the line of MV 
coaptation. 
 
The decision to release the clip is made on the basis of: 
1. improved mitral valve coaptation/ reduced size of mitral regurgitation jet; 
2. the stability of the device judged by the length of the leaflets grasped by its closed arms and 
compared with their pre-treatment length;  
3. mean MV pressure gradient <5 mm Hg. 
Echocardiographic 3D-guided planimetry of the resulting double valve orifices is also helpful 
in the decision-making process. 
During the procedure significant manipulations should be avoided to minimize chordal and 
subchondral entanglement, which may damage to the mitral subvalvular apparatus. The 
decision on multiple clip implantation depends on the MR reduction grade after the first 
MitraClip device deployment, the width of the baseline coaptation defect, the transvalvular 
gradient, and the presence of the clefts. Recently available clips with wider grasping area allow 
to reduce the number of clips required. Until the clip is released from the delivery system, it 
can be repositioned as needed. After the MitraClip system has been deployed and released, 
residual regurgitation and stenosis are assessed (with a mean gradient ≤5 mm Hg and heart rate 
≤80 beats/min) as well as clip stability and presence of excessive pericardial fluid. 3D 
planimetry is also a useful tool in assessing the residual mitral valve area. The entire procedure 
should be preceded with a detailed analysis of each stage and in an agreement between the 
operator and interventional imaging cardiologist. It is of utmost importance to obtain an optimal 
MR reduction to provide better outcomes.  
 
Type of anesthesia 
MitraClip implantation procedures are performed under general anesthesia. It enables, i.a short-
term respiratory arrest, facilitating the positioning of the system and grasping the leaflets of the 
valve in certain cases of high respiratory mobility. Recently published data suggest the safety 
of MitraClip procedures under deep analgosedation instead of general anesthesia, but this is not 
yet the recommended standard of practice [Horn, 2017 #1299]. Furthermore, general anesthesia 
improves patients’ tolerance to TEE probe placement in the supine position and ensures 




Due to the large-caliber delivery system (24F diameter; 8.1 mm), appropriate hemostasis 
management is required. The following techniques are available: a) prolonged manual 
compression; b) “8” or “Z” suture, as well as; c) off-label use of the pre-closure technique (1–
2 Proglide sutures); d) combining techniques a–c. 
There are no prospective studies aiming to compare the efficacy of different methods [16]. 
 
Anticoagulant and antiplatelet therapy 
Activated Clotting Time (ACT) should be monitored regularly during the procedure. Target, 
therapeutic ACT level above 250–300 sec should be maintained. The timing of heparin 
administration varies. Most operators administer the full dose prior to transseptal puncture 
(TSP), others wait until puncture has occurred or administer half the dose prior to puncture and 
the other half after TSP. The optimal time to initiate anticoagulation has not been studied so 
far. There is no reliable scientific evidence that would enable clear recommendations' 
formulation regarding anticoagulant and antiplatelet treatment after the procedure. In patients 
without indications for anticoagulation, dual antiplatelet therapy with acetylsalicylic acid for 6 
months is used, together with clopidogrel for the first month. Oral anticoagulation (Vitamin K 
antagonist or Non-Vitamin K antagonists oral anticoagulant) is required in patients with atrial 
fibrillation. An individual bleeding risk assessment is required. Each center should develop an 




Along with echocardiographic assessment, additional information is provided by monitoring 
mean left atrium pressure (mLAP). No decrease or increase in mLAP after surgery is associated 
with a higher risk of readmission in long-term follow-up for HF regardless of residual MR on 
TEE [17]. It is reasonable to measure mLAP during edge-to-edge repair procedures to evaluate 
the effectiveness of the intervention and assess the prognosis. Post-operative evaluation of 
pulmonary venous flow reversal as an indirect parameter of the effectiveness of the procedure 
is also important.  
 
Iatrogenic atrial septal defect after transcatheter mitral valve repair  
MitraClip placement requires interatrial transseptal puncture (IAS), which due to the relatively 
large delivery system and guiding catheter (≥22 F), creates an atrial septal defect (ASD). It 
which may close spontaneously or remain patent after the procedure (incidence 50%–85% after 
30 days and <30% after 12 months, defects <7–8 mm are more likely to close spontaneously). 
Factors favoring the formation of iatrogenic ASD (iASD) include the diameter of the delivery 
system, long surgery duration, multiple manipulations with the delivery system, left ventricular 
hypertrophy, delivery system maneuvers, and increased post-operative left atrial pressure.  
In terms of hemodynamic consequences, post-operative ASD may cause: 
1. acute complications immediately after the procedure: severe left-to-right shunt with 
hypoxemia and acute heart failure (approximately 1.5% of patients); 
2. chronic complications associated with left-to-right or bi-directional shunt (right 
ventricular overload, pulmonary hypertension); 
3. pressure relief of the left atrium with no negative impact; 
4. no hemodynamically significant consequences. 
The right-to-left shunt is associated with a subsequent worse 12-month prognosis than the 
left-to-right shunt. 
In case of acute respiratory failure, it is recommended to close the iASD immediately after the 
TMVR procedure with a dedicated occluder, using TEE guidance to assess the size of iASD . 
The long-term approach to postprocedural ASD with a persistent hemodynamic effect (L-R 
shunt) is controversial. The data from the registries are contradictory and show both the 
beneficial effect of left atrial decompression on HF symptoms, as well as the progression of HF 
and worsening of prognosis [20]. The randomized MITHRAS trial, in which the primary 
endpoint was changes in the 6-minute walk test distance, did not show transcatheter iASD 
closure superiority over conservative therapy in terms of functional outcomes [21].  
 
Summary 
Routine closure of the iASD is not recommended in patients after edge-to-edge repair 
procedures unless there is hemodynamic instability and peri-procedure hypoxemia. 
The decision to close the defect in an elective procedure depends on the hemodynamic 
significance of the shunt (right ventricular overload, pulmonary hypertension) and the risk of 
paradoxical embolism (venous thromboembolism, history of pulmonary embolism). Operators 
should be acquainted with ASD closure procedure; different sizes of ASD occluders ought to 
be available in the laboratory.  
 
Procedural Complications and Complication Management: 
Periprocedural complications include: 
— perioperative death (<2%); 
— bleeding at the access site of various severity, including major bleeding requiring transfusion 
(to 17.2%) [22]; 
— early partial leaflet detachment (1%–4.8%); 
— clip embolization (<0.05%); 
— leaflet perforation, mitral chordae rupture (0.8%); 
— cardiac perforation and pericardial tamponade (0.7%); 
— thrombus formation within the left atrium (approx. 9%); 
— stroke and transient ischaemic attack (0.9%–1.3%); 
— renal failure (4.2%); 
— oesophageal damage (0.6%–2.8%); 
— gas embolism. 
The formation of an atrial thrombus and/or on the device is an indication for prolonged heparin 
therapy in therapeutic doses and echocardiographic control prior to hospital discharge. Once 
the thrombus resolves, the use of an oral anticoagulant and regular echocardiographic 
monitoring should be considered.  
In a small percentage of cases, patients with transcatheter treatment failure require urgent 
cardiac surgery. The incidence is rare (<0.5%), and the number of cases decreases with the 
increasing experience of operators and centers [23]. In case of complete dislodgement of the 
MitraClip, if it is not possible to achieve a reduction of the reverse wave or a significant 
narrowing of the mitral valve after the implant is released. In case of unsatisfactory MR 
reduction, dislocation of the clip, or relevant postprocedural mitral stenosis, surgical treatment 
should be considered. Complete clip detachment or clip embolization usually requires 
conventional surgery. Partial leaflet detachment of the clip may occur periprocedural period or 
after the procedure. Half of the patients with late MitraClip single leaflet detachment are treated 
conservatively. In case of unsuccessful initial repair and development of severe recurrent MR, 
repeated MitraClip procedure is a feasible treatment option for high/prohibitive risk patients. 
In some patients, it is necessary to consider surgical treatment if the placement of the clip causes 
ischemia. 
 
Postprocedural clinical assessment 
Transthoracic echocardiography evaluation prior to hospital discharge is recommended. 
Echocardiographic reassessment after approximately 30 days, 6 months, and 1 year is justified.  
It is useful to evaluate the volume of the left ventricle, the size of the left atrium and the 
pulmonary venous flow (indirect parameters indicative of a permanent reduction of the 
regurgitant jet), as well as the size of the iASD, right ventricular function and pulmonary 
hypertension. During the post-operative evaluation, it is also necessary to perform routine 
laboratory tests, optimize pharmacotherapy and evaluate the compliance with guideline-
recommended anticoagulant and/or antiplatelet therapy.  
 
Alternative uses of MitraClip system (early stages of clinical testing) 
Limited data from the registers suggest safety and efficacy of MitraClip procedures in MR 
correction in selected patients from the following groups: patients considered for orthotopic 
heart transplantation (OHT) or implantation of a left ventricular assist device (LVAD) as a 
bridge procedure providing hemodynamic support; in patients with residual regurgitation jet 
after surgical mitral valve repair; in patients with severe symptomatic MR related to obstructive 
hypertrophic cardiomyopathy to eliminate systolic anterior motion of the mitral valve; in 
therapy-resistant cardiogenic shock related to decompensated HF and concomitant severe 
chronic MR and in patients with acute MR. There is no clinical data to support the long-term 
effectiveness of this approach. Decisions in such cases should be made by a multidisciplinary 
team [24]. Edge-to-edge procedures are increasingly performed in patients with concomitant or 
isolated tricuspid regurgitation in order to reduce the tricuspid regurgitant jet velocity [2, 3].  
 
Institutional and operator requirements 
Operator: It is recommended that the learning curve of operators and echocardiographers 
include the first 50 patients with optimal MV morphology, and then patients in the conditionally 
acceptable MV anatomy group may be treated. 
Pursuant to the regulation of the Ministry of Health of November 12, 2015, specifying the 
conditions for highly specialized services, transcatheter non-surgical repair of the mitral valve 
in high-risk patients may be performed in centers that meet, among other things, the following 
requirements: 1) hybrid cardiac catheterization laboratory; 2) interventional radiology or 
catheterization laboratory; 3) intensive post-operative care in conditions equivalent to intensive 
care. The team performing the procedure should have extensive documented experience in 
mitral valve repair (cardiac surgeon) or transcatheter treatment of structural heart disease 
(cardiologist), as well as an available specialist in echocardiographic imaging, an 
anesthesiologist, surgical nurses, and perfusionist. Supervision over the patient after the 
procedure is performed, apart from the intensive care or intensive cardiac care unit staff, also 
by a team consisting of a cardiac surgeon, cardiologist, and a nurse, specialized in the field of 
anesthetic and intensive care nursing.  
In addition, the regulation specifies requirements for the team's experience (10 transcatheter 
non-surgical mitral valve repair/replacement procedures in high-risk patients performed) as 
well as the eligibility criteria: 
a) patients with severe symptomatic MR (EROA >0.3 for functional and >0.4 for primary MR); 
b) disqualified by a multidisciplinary team from classical (surgical) or minimally invasive 
surgical treatment due to documented high cardiac surgery risk; 
c) the patient selection process is performed by the heart team. 
Procedures should be reported as a part of the National Registry of Cardiac Surgery Procedures 
— however, it seems advisable to create a dedicated register covering all transcatheter edge-to-
edge procedures, enabling a reliable follow-up assessment of short and long-term results of the 
procedure. 
 
Percutaneous mitral valve procedures during COVID-19 pandemic 
Recently published expert opinion of the Working Group on Valvular Heart Diseases, the 
Working Group on Cardiac Surgery, and the Association of Cardiovascular Interventions of the 
Polish Cardiac Society emphasize the need to reduce the risk of patients and staff infection with 
SARS-CoV-2 virus. Simultaneously, it is crucial that patients with symptomatic HF, despite 
guideline-directed medical therapy, have the opportunity for interventional treatment of the 
MR, which may positively affect the quality of life improvement and patients’ prognosis [25]. 
 
DEVICES FOR PERCUTANEOUS CORRECTION OF MITRAL REGURGITATION, 
WITH THE “CE” MARK, THE USE OF WHICH HAS NOT BEEN INCLUDED IN 
THE CURRENT ESC/PTK RECOMMENDATIONS PUBLISHED IN 2017 
Carillon mitral contour system (Cardiac Dimension Inc., Kirkland, WA, USA) is the only 
device for percutaneous indirect mitral valve annuloplasty which has obtained the “CE” mark. 
The device is intended for the treatment of patients with functional MR. The Carillon device 
incorporates two self-expanding anchors and a preshaped connecting bridge segment. The 
implantation procedure is performed using a venous approach under general anesthesia under 
the guidance of TEE. When delivered percutaneously to the coronary sinus, the Carillon device 
causes a decrease in the mitral annulus size and subsequently significantly reduces mitral 
regurgitant volume. If the obtained effect is suboptimal or compression of or obstruction to flow 
in the circumflex coronary artery or its branches is observed, the device can be folded and 
removed. AMADEUS (CARILLON Mitral Annuloplasty Device European Union Study), 
TITAN (Tighten the Annulus Now), and TITAN II studies have shown that mitral annuloplasty 
using the Carillon system significantly improves the quality of life by reducing MR, as well as 
physical performance assessed with the 6-minute walk test in patients with FMR [26]. In 2019, 
the results of a multicentre, blinded, randomized, sham-controlled REDUCE-FMR (Carillon 
Mitral Contour System for Reducing Functional Mitral Regurgitation) trial were published. One 
hundred twenty patients receiving optimal heart failure medical therapy were randomized to 
either, Carillon system implantation group for mitral annular reduction or sham-controlled arm. 
At one year, a statistically significant reduction in mitral regurgitant volume in the treatment 
group compared to the control group (decrease of 7.1 ml/beat vs an increase of 3.3 ml/beat 
respectively; P = 0.049), left ventricular end-diastolic volume decrease (of 10.4 ml vs an 
increase of 6.5 ml; P = 0.03) and left ventricular end-systolic volume decrease (of 6.2 ml vs an 
increase of 6.1 ml; P = 0.04) were observed. When implanting the Carillon device, it should be 
remembered that perforation of the thin-walled coronary sinus is a possible procedural 
complication and that in some patients, the circumflex coronary artery may be compressed with 
subsequent flow obstruction. For the above reasons, 14% of patients were not implanted with 
Carillon in the REDUCE-FMR study [27]. Indirect mitral annuloplasty using Carillon is an 
effective treatment method that reduces MR and results in favorable left ventricular remodeling. 
However, the device is now used relatively infrequently in daily clinical practice. 
Cardioband mitral system (Edwards Lifesciences, Irvine, CA, USA) is intended for 
percutaneous, direct mitral valve annuloplasty in patients with functional MR. The procedure 
is performed under general anesthesia guided by TEE. The device is delivered through a 
femoral venous puncture. The most crucial part of the Cardioband is a polyester-covered wire, 
which is successively attached to the back of the patient's native mitral ring with a number of 
anchors, and after the insertion, it resembles an incomplete surgical ring. The mitral annulus is 
then reduced in size using a unique regulating tool under the TEE guidance to minimize MR. 
In 2019, a multicentre study was published, which demonstrated the impact of Cardioband 
directly after implantation and at 12-months in 60 patients with echocardiographically assessed 
moderate (27%) or severe (73%) secondary MR. Technical success was achieved in 97%, 
device success in 72%, and procedural success in 68% of patients. In addition, there was a 
significant reduction of the septolateral diameter (3.7 ± 0.4 vs 2.6 ± 0.4 cm; P <0.01). Mitral 
regurgitation grade (in alive patients free of reintervention) and at 12 months was mild in 69%, 
moderate in 26%, and severe in 5% of patients. Anchor disengagement was observed in 10 
patients, resulting in device inefficacy in 5 patients. In none of these patients did the device 
migrate or had detached from the mitral ring. In the follow-up, six patients required 
percutaneous MR correction. During Cardioband implantation, care should be taken not to 
injure a coronary artery with the anchor while securing the ring [28].  
The Cardioband customized annular reduction procedure reduces MR; therefore, it can be 
assumed that role of Cardioband in the treatment of functional MR will significantly increase 
in the future. 
 
TRANSCATHETER CHORDAL REPAIR IN MR 
Neochord DS 1000 (Neochord Inc., St. Louis Park, MN, USA) and Harpoon (MVRS, Edwards 
Lifesciences, Irvine, CA, USA) systems, which both received CE mark approval, allow 
transesophageal echocardiography-guided (2D and 3D) transapical, beating-heart MV repair 
with insertion of prosthetic chords. The Neochord system allows the implantation of artificial 
chords to the edges of MV leaflets by capturing the leaflets and their puncture with a needle. 
The Harpoon system obtains the leaflet capture via a double helix-shaped knot on the atrial 
aspect of the leaflet after its puncture by the integrated needle. In both systems, the length of 
the chords is adjusted under echocardiography guidance, and the apical end of the chords is 
secured on the external surface of the heart. In both methods, implantation of at least 3 chords 
is recommended. Neo-chord implantation is dedicated to patients fulfilling anatomical criteria, 
e.g. The sum of the leaflet lengths should be at least 20% larger than the anterior-posterior 
dimension of the mitral annulus to achieve the coaptation of 5 mm. In the Neochord group, the 
best results were obtained in patients with elongated or ruptured chordae tendineae to the P2 
segment of the posterior leaflet [29]. The Harpoon system has so far only been used in patients 
with P2 pathology. 
Numerous observational studies have demonstrated the safety and effectiveness of both 
methods; therefore, they are already widely used clinically [30, 31]. Harpoon device is equipped 
with a hemostatic introducer that minimizes intraoperative bleeding. Due to the lack of a 
dedicated hemostatic sheath, it is recommended to use the Cell Saver system with Neochord 
technique. The validity of these techniques has been documented extensively in a 5-year follow-
up. Initial reports on large groups showed that 10%–35% of patients have greater than moderate 




TRANSSEPTAL TRANSCATHETER IMPLANTATION OF DEDICATED MITRAL 
VALVE BIOPROSTHESIS (UNDER CLINICAL TRIALS) 
Edge-to-edge MR correction procedures, although effective and safe in the majority of patients, 
are subject to numerous limitations. About 10% of patients have a significant residual MR, 25% 
have a gradient of 5 mm Hg or higher in post-operative evaluation. What is more, the 
MitraClip/Pascal system is contraindicated in a number of candidates, and recurrent MR after 
the intervention still remains a challenge. The learning curve for the MitraClip procedure 
flattens after 200 procedures. Therefore, it is justified to look for a better solution, such as 
percutaneous mitral valve implantation via transseptal approach. Several systems are currently 
evaluated in preclinical and clinical trials. Some of the systems were discontinued, or the 
investigation has been temporarily suspended due to observed complications (e.g., valve 
thrombosis). TMVI is a more far complex procedure than TAVI due to the anatomy of the 
mitral valve, risk of the obstruction of the LVOT, a larger size of the delivery systems, and 
sometimes difficulties in maneuvering the device in the left atrium. Furthermore, patients 
treated with TMVI often have multiple baseline comorbidities, making the 30-day mortality 
very high, ranging from 18% to even 60% [4]. It should be noted that the papers published so 
far are based on relatively small groups of patients. At present, the prospect of routine trans-
septal TMVI procedures is distant. The systems described below were used in Poland in only a 
few eligible candidates.  
High Life Valve (HighLife Medical Inc., Irvine, CA, USA) is a self-expanding bioprosthesis 
that consists of a nitinol alloy-based frame covered with a polyester graft and trileaflet bovine 
pericardium with an annular diameter of 28 mm.  
The first stage of the procedure is placing a ring-shaped implant through the aortic valve around 
the subvalvular apparatus. The ring ensures proper fixation for the prosthesis. Subsequently, a 
self-expanding prosthesis is delivered transseptally and implanted into the ring. So far, five 
successful procedures have been performed in Poland with the use of High-Life bioprosthesis. 
In total, approximately 30 treatments have been performed using this valve in the world. In 
preparation for the procedure, computed tomography plays a key role, which allows assessing 
the risk of LVOT obstruction, one of the basic eligibility criteria.  
 
IMPLANTATION OF DEDICATED TRANSCATHETER MITRAL VALVE 
BIOPROSTESIS VIA TRANSAPICAL ACCESS 
Transapical TMVI has emerged to be a promising alternative to edge-to-edge repair. 
Transcatheter mitral valve replacement systems designed for transapical delivery that are still 
evaluated in clinical trials but for which already quite extensive clinical experience is available 
are Tendyne Bioprostehsis (Abbott Inc, USA), Intrepid Valve (Twelve Inc, Medtronic Inc., 
Fridley, MN, USA), CardiAQ (Edwards Lifesciences, Irvine, CA, USA), Tiara (Neovasc, 
Richmond, Canada) and Gate Valve (Navigate Inc., James Bay, CA USA). Some of the 
abovementioned have already received the European CE mark (Tendyne), and others are still 
in the clinical trial phase. In a simplified manner, the procedural technique consists of gaining 
access to the left ventricle through a large dedicated delivery sheath on and precise off-pump 
implantation (during rapid ventricular pacing) of a mitral valve bioprosthesis into the native 
mitral annulus or into the leaflets of the patient's calcified native valve. Procedural guidance is 
mainly performed under fluoroscopy and TEE assistance.  
TENDYNE (Abbott Cardiovascular, Plymouth, MN, USA) valve is currently the only CE-
approved and commercially available transcatheter mitral valve implant. However, unlike the 
previous valves, it is implanted via a transapical approach. The valve consists of 2 Nitinol self-
expanding joined stents with three porcine pericardial leaflets sewn into the frame. The system 
is anchored with the use of a tether and epicardial pad to the apex of the heart. In a registry of 
100 patients with severe heart failure and reduced left ventricular ejection fraction, the technical 
success of the procedure was 96%, the 30-day mortality was 6%, and the 1-year survival was 
72.4%. Directly after the procedure, 98.9% of patients had none-trace mitral regurgitation, and 
98.4% at one year [34].  
 
CONCLUSIONS 
In patients with severe symptomatic primary MR, cardiac surgery is the treatment of choice. In 
patients at high or prohibitive surgical risk, a catheter-based percutaneous edge-to-edge repair 
technique to correct mitral regurgitation has emerged as a feasible alternative therapeutic 
option. Patients with secondary MR and HF, despite optimal pharmacological therapy and CRT, 
benefit from edge-to-edge procedures when the dominant mechanism of HF is mitral 
regurgitation rather than end-stage left ventricular dysfunction. 
In both types of MR, referral for transcatheter treatment is a consensus of a multidisciplinary 
team consisting of a cardiac surgeon, interventional cardiologist, noninvasive cardiologist, 
interventional imaging specialist, and anesthesiologist. It is crucial to assess the predicted 
survival time and the probability of achieving an effective reduction of the regurgitation jet. 
Current ESC/EACTS guidelines on management of the valvular heart disease presented at the 
ESC Congress in August 2021 reinforce the heart team-based approach to patients’ selection 
and qualification for edge-to-edge repair. Preferably the patients should fulfill the clinical and 
anatomic criteria compatible with the COAPT (high likelihood of improvement). The class of 
indications is IIa with level of evidence (LOE) B for patients not eligible for surgery and with 
high likelihood of improvement and IIb LOE C in selected high-risk symptomatic patients not 
eligible for surgery and not meeting the criteria of increased chance of response to edge-to-edge 
repair [35]. It should be emphasized that LVAD implantation or OHT are highly effective 
treatment options for patients whose dominant symptom mechanism is heart failure and left 
ventricular damage. The results of the transcatheter treatment of MR should be quality 
controlled, preferably through a national registry. The population of patients requiring the 
minimally invasive transcatheter treatment because of the comorbidities and surgical risk is 
substantial. The access to such technologies in Poland is scarce and should be facilitated. The 
number of procedures is too low (<190 procedures in 2020) to meet the clinical needs. The 
Valve-for-Life initiative of the European Association of Percutaneous Cardiovascular 
Interventions supports the evidence-based implementation of transcatheter valve technologies 
in Poland (www.aisn.pl).  
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Table 1. Similarities and differences between MITRA-FR and COAPT studies with respect to 
echocardiographic characteristics and procedural outcomes immediately and at one year post-
procedure. 
Abbreviations: COAPT, Cardiovascular Outcomes Assessment of the Mitra-Clip Percutaneous 
Therapy for Heart Failure Patients with Functional Mitral Regurgitation; EROA, effective 
regurgitant orifice area; LVEDV, ventricular end-diastolic volume; LVEF, left ventricular 
ejection fraction; MITRA-FR, Percutaneous Repair with the MitraClip Device for Severe 




Mitra FR (n = 304) COAPT (n = 614) 





EROA >20 mm2 
RV >30 ml 
31 ± 10 mm2 
135 ± 35 ml/m2 
15%–40% 
EROA >30 mm2 
RV >45 ml 
41 ± 15 mm2 
101 ± 34 ml/m2  
20%–50% 
Medical therapy at baseline 
and during follow-up 
Multiple adjustments in 
medical treatment were 
allowed 
Medical treatment was optimized 
prior to randomization, only minor 





Procedural complications 14.6% 8.5% 
MR ≥3+ at 12 months 17% 5% 
 
Figure 1. Algorithm for management of patients with significant symptomatic MR. Based on: 
[14] and [35]. 
 
 
 
 
 
